secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001628280-25-013875
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland's ifetroban shows 5.4% cardiac improvement in DMD Phase 2 trial
--------------------------------------------------------------------------

- High-dose ifetroban improved LVEF by 3.3% vs. placebo and 5.4% vs. natural history controls.
- Results from FIGHT DMD trial selected for late-breaking presentation at MDA Clinical & Scientific Conference.
- Ifetroban has FDA Orphan Drug and Rare Pediatric Disease Designations for DMD heart disease.
- End-of-Phase-2 meeting with FDA planned to discuss next steps for development and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828025013875/0001628280-25-013875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828025013875/cpix-20250319.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-013875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer